CAPLIPOINT:NSE-Caplin Point Laboratories Limited (INR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSE

Last Closing Price

INR 577.55

Change

0.00 (0.00)%

Market Cap

INR 43.67B

Volume

1.44M

Average Target Price

INR 650.00 (+12.54%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Caplin Point Laboratories Limited develops, manufactures, markets, and exports generic pharmaceutical formulations and branded generic products in India and internationally. It provides tablets, capsules, vials, ophthalmic products, liquid orals, soft gel capsules, ointments, creams and gels, powder for injections, suppositories and ovules, dermo cosmetics, surgicals and disposables, pre-mix bag formulations, inhalers and sprays, IV infusion products, dry syrups, topicals, and other products, as well as liquid, lyophilized, and pre-filled injection syringes. The company also operates QueTenX, an e-commerce website. Caplin Point Laboratories Limited was founded in 1990 and is based in Chennai, India. Address: Ashvich Tower, Chennai, India, 600096

Company Website : http://www.caplinpoint.net

Address : Ashvich Tower, Chennai, India, 600096

Employees : 1,696

Fiscal Year End : March

Currency: INR

Country : India

Technical Indicators

Beta : 0.76

52 Week High : 685.52

52 Week Low : 304.89

200 Day Moving Average : 480.91

50 Day Moving Average : 473.39

Shares Held By Insiders : 761.5700000000001%

Shares Held by Institutions : 2.75%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-09 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

N/A

 INR1,630.22B 67.65 33.42
DIVISLAB:NSE Divi's Laboratories Limited

N/A

 INR1,069.60B 57.18 38.87
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

N/A

 INR860.37B 40.48 21.10
CADILAHC:NSE Cadila Healthcare Limited

N/A

 INR617.42B 33.46 20.26
AUROPHARMA:NSE Aurobindo Pharma Limited

N/A

 INR593.59B 11.03 7.25
LUPIN:NSE Lupin Limited

N/A

 INR542.48B 47.48 19.74
ALKEM:NSE Alkem Laboratories Limited

N/A

 INR347.63B 22.67 15.84
LAURUSLABS:NSE Laurus Labs Limited

N/A

 INR261.57B 26.66 17.56
IPCALAB:NSE Ipca Laboratories Limited

N/A

 INR260.88B 24.43 17.01
APLLTD:NSE Alembic Pharmaceuticals Limite..

N/A

 INR185.01B 15.49 12.17

ETFs Containing CAPLIPOINT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.34% 53% F 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.34% 50% F 58% F
Trailing 12 Months  
Capital Gain 79.70% 45% F 49% F
Dividend Return 0.12% 10% F 3% F
Total Return 79.82% 44% F 49% F
Trailing 5 Years  
Capital Gain 205.70% 80% B- 87% B+
Dividend Return 3.60% 76% C 43% F
Total Return 209.29% 80% B- 86% B
Average Annual (5 Year Horizon)  
Capital Gain 25.67% 69% D+ 83% B
Dividend Return 0.36% 38% F 28% F
Total Return 26.04% 68% D+ 82% B-
Risk Return Profile  
Volatility (Standard Deviation) 67.32% 32% F 24% F
Risk Adjusted Return 38.68% 68% D+ 76% C
Market Capitalization 43.67B 58% F 74% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 19.59 59% F 52% F
Price/Book Ratio 3.75 54% F 25% F
Price / Cash Flow Ratio 97.74 12% F 3% F
EV/EBITDA 10.72 72% C- 56% F
Management Effectiveness  
Return on Equity 24.38% 87% B+ 93% A
Return on Invested Capital 21.52% 91% A- 93% A
Return on Assets 14.02% 89% B+ 96% A
Debt to Equity Ratio 0.00% 87% B+ 89% B+
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.76 56% F 71% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.